NasdaqGS:SVRABiotechs
A Look At Savara (SVRA) Valuation After Recent FDA Progress And Strengthened Outlook
Why Savara’s recent FDA progress is back in focus
Savara (SVRA) is back on investor radars after resubmitting its biologics license application, completing a tech transfer to Fujifilm, and aligning key analytical protocols with the FDA.
With an FDA filing decision expected in the near term and management expressing strong confidence in the updated package, the upcoming Guggenheim Securities Emerging Outlook, Biotech Summit presentation on February 11 is drawing extra attention from...